InMed Pharmaceuticals
Company Information
InMed Pharmaceuticals is a Vancouver-based clinical-stage pharmaceutical company developing proprietary small-molecule therapeutics that target CB1 and CB2 receptors. Its pipeline includes programs for Alzheimer’s disease, dry age-related macular degeneration and dermatological indications, and the company also references manufacturing and R&D capabilities through its broader platform.
Industry Focus and Technologies
Small molecule therapeutics, cannabinoid science, CB1 and CB2 receptor targeting, clinical-stage drug development, neuroinflammation, ophthalmology, dermatology, and pharmaceutical research and development.
Location
Vancouver, British Columbia, Canada
Company Size and Stage
Products, Platforms or Focus Areas
INM-901 for Alzheimer’s disease, INM-089 for dry age-related macular degeneration, INM-755 for epidermolysis bullosa, and related small-molecule therapeutic development programs.